Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Completed × tafasitamab × Clear all

Phase

Phase 2 4 Phase 1 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Fluorouracil 21 Cisplatin 20 Oxaliplatin 15 Gemcitabine 15 Radiotherapy 14 Docetaxel 14 Paclitaxel 13 Capecitabine 13 Carboplatin 12 Bevacizumab 12 Leucovorin 11 Cyclophosphamide 11 Irinotecan 10 Drug Therapy 10 Cytarabine 9 Magnetic Resonance Spectroscopy 7 Dexamethasone 7 Saline Solution 6 Rituximab 6 Nivolumab 6 Methotrexate 6 Letrozole 6 Exercise 6 Etoposide 6 Electroporation 6 pembrolizumab 5 Melphalan 5 Lidocaine 5 Filgrastim 5 Doxorubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02763319 2025-07-17

B-MIND

Incyte Corporation

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡